Genetic mutations that activate oncogenes such as KRAS2 and NRAS [2], and loss of function in tumor suppressors such as RB1, TP53, PPP2R1B, CDKN2A, and TSLC1 have been demonstrated in NSCLC tumors [3-7]. This evidence concerns the gene CADM1 and neoplasm.